Proteomics technology company Evosep has received an investment of $40m from global life science investor Novo Holdings to advance clinical proteomics applications.
Evosep will use the funds to advance the proteomics applications enabled by its standardised liquid chromatography platform.
Additionally, Evosep will be able to use the investment to expand its presence across the globe, especially in the growing US market.
This expansion will provide more customers with a high-throughput proteomics solution.
Novo Holdings principal Stephen Van Helden said: “Evosep’s technology can profoundly impact the diagnosis and treatment of diseases.
“Its platform addresses some of the most common technical pain points that have historically held back the widespread application of proteomics.”
Concurrent with Novo Holdings’ investment, Van Helden will join the Board of Directors of Evosep.
Founded in 2016, Evosep was established to improve patient care and quality of life by unlocking liquid chromatography-mass spectrometry (LC-MS) for the discovery of drugs as well as innovating the way protein-based clinical diagnostics are performed across several protein biomarker panels.
Evosep CEO Christian Ravnsborg said: “We are delighted to have Novo Holdings A/S as a new shareholder in Evosep. Novo Holdings is a well-known and highly regarded long-term investor with significant expertise in working with innovative life sciences businesses to unlock their potential.
“The combined experience and investment will enable us to accelerate our already strong growth and further expand our platform towards bedside care proteomics, both independently and through our many vendor relationships.”
Denmark’s Export and Investment Fund, which has been making investments in Evosep since 2016, is among the company’s other existing investors.
Evosep offers high-sample-throughput capability between sample runs and across sites and instruments.